Medical Societies Release Flu Vaccine Guidance as CDC Advisory Panel Remains in Limbo
Medical societies stepped in with flu vaccination advice after the CDC advisory panel was blocked by litigation. Recommendations cover universal flu shots, enhanced options for seniors, the new mRNA product, and narrowed COVID guidance for high-risk groups. Data show meaningful hospitalization reductions but highlight coverage gaps created by the regulatory vacuum.
The guidance emphasizes universal vaccination starting at age 6 months, with enhanced options for adults 65 and older and a new mRNA vaccine approved for ages 50+. Last season's data showed a 31% reduction in hospitalizations among older adults who received standard shots. Societies stressed that pregnancy, asthma, diabetes, and immunosuppression remain key risk factors, noting the prior two seasons' high pediatric mortality concentrated among unvaccinated children.
Multiple enhanced vaccines and the first mRNA flu product (Moderna mFLUSIVA) now compete with standard and nasal-spray formulations. One trial reported 27% greater effectiveness of the mRNA candidate versus standard shots in 50- to 64-year-olds. Recommendations for COVID-19 boosters were narrowed to higher-risk groups, with seniors advised to receive two doses six months apart.
The absence of updated federal guidance has created uneven insurance coverage and state policies. Physician groups filled the vacuum by publishing evidence summaries that mirror prior ACIP language while adding explicit calls for simultaneous COVID and RSV vaccination where indicated.
Next steps include monitoring early-season effectiveness data and clarifying whether the court case will delay the 2027 ACIP schedule.
CDC: At least two states will issue emergency vaccine purchase orders bypassing ACIP by December 2026 if litigation persists.
Sources (3)
- [1]MedicalXpress coverage of society guidelines(https://medicalxpress.com/news/2026-10-experts-ideal-flu.html)
- [2]Vaccine Integrity Project hospitalization data release(https://www.cidrap.umn.edu/influenza-vaccines)
- [3]FDA approval notice for mFLUSIVA(https://www.fda.gov/vaccines-blood-biologics)